Language selection

Government of Canada / Gouvernement du Canada

Search

NPDUIS Analytical Studies

National Prescription Drug Utilization Information System (NPDUIS) publishes a variety of studies that provide Canadians with comprehensive information on drug pricing, utilization, and cost trends in Canada and internationally. These include annual publications, report series, focused research reports, journal articles, and presentations.

Annual Publications

CompassRx: Annual Public Drug Plan Expenditure Report

9th Edition
Published: December 2023
PDF 1.2 MB

Previous Editions

Meds Entry Watch

8th Edition
Published: May 2024
PDF 1,2 MB

Supplementary Information

Previous Editions

Meds Pipeline Monitor

2023 Edition
New Published: November 2024
PDF 9.6 MB

Previous Editions

Previous Editions

CompassRx: Annual Public Drug Plan Expenditure Report
table - Previous Editions
Edition Published Pdf
CompassRx, 8th Edition, 2020/21 January 2023 908 KB
CompassRx, 7th Edition, 2019/20 November 2021 2.5 MB
CompassRx, 6th Edition, 2018/19 December 2020 2.4 MB
CompassRx, 5th Edition, 2017/18 September 2019 2.25 MB
CompassRx, 4th Edition, 2016/17 September 2018 2.80 MB
CompassRx, 3rd Edition, 2015/16 May 2017 2.26 MB
CompassRx, 2nd Edition, 2013/14 May 2016 4.02 MB
CompassRx, 1st Edition, 2012/13 March 2015 4.37 MB
Analysis Brief: CompassRx, 2012/13 March 2015 804 KB

Meds Entry Watch
table-meds entry watch editions
Meds Entry Watch Edition Published Pdf
7th Edition August 2023 PDF 497 KB
6th Edition April 2022 PDF 592 KB
5th Edition, 2019 February 2021 4.7 MB
2018 Edition January 2020 899 KB
2017 Edition February 2019 3.35 MB
2016 Edition June 2018 758 KB
2015 Edition April 2017 2.33 MB

Meds Entry Watch - Supplementary Information
table-meds entry watch supplementary
New Medicines Approved in Pdf
2021 143 KB
2020 101 KB
2019 165 KB
2018 127 KB
2017 97 KB
2016 97 KB

Meds Pipeline Monitor
Previous Editions
Meds Pipeline Monitor Edition Published Pdf
2022 Edition April 2022 1.43 MB
2021 Edition April 2022 2.7 MB
2020 Edition January 2021 4.1 MB
2019 Edition April 2020 2.4 MB
2018 Edition May 2019 1.94 MB
New Drug Pipeline Monitor
7th Edition December 2015 1.43 MB
6th Edition December 2014 723 KB
5th Edition December 2013 -
4th Edition April 2013 -
3rd Edition July 2011 -
2nd Edition July 2008 -
1st Edition June 2007 -

Back to top

Report Series

Formularies in Canada

Formularies in Canada

Part 3: Medicines Assessed by the Common Drug Review
Published: February 2022
PDF 1.9 MB

Previous Editions

Generics360: Generic Drugs in Canada

Generic360

2018 Edition
Published: August 2019
PDF 1.10 MB

Previous Reports

Market Intelligence Report

Antidiabetic Drugs, 2012-2021
Published: May 2023
2.1 MB

Previous Reports

Private Drug Plans in Canada

Private Drug Plans in Canada - Part 1: Generic Market 2005–2013

Part 1: Generic Market 2005–2013
Published: December 2015
PDF 3.02 MB

Previous Editions

Formularies in Canada
formulaire - Previous Editions
Formularies in Canada Edition Published Pdf
Part 2: Oncology Medicines May 2021 2 MB
Part 1: General Overview October 2017 2.07 MB
List of Selected Drugs October 2017 1 MB

Generics360: Generic Drugs in Canada
generics360 Reports
Generics360: Generic Drugs in Canada Report Published Pdf
Generics360: Generic Drugs in Canada - 2016 Edition February 2018 1.19 MB
Generics360: Generic Drugs in Canada - 2014 Edition February 2016 1.76 MB
Generic Drugs in Canada, 2013 December 2014 645 KB
Analysis Brief: Generic Drugs in Canada, 2013 December 2014 182 KB
Analytical Snapshot: International Generic Price Comparison, Early 2011 August 2013 899 KB
Generic Drugs in Canada: International Price Comparisons and Potential Cost Savings September 2011 368 KB
Generic Drugs in Canada: Market Structure – Trends and Impacts December 2010 310 KB
Generic Drugs in Canada: Price Trends and International Price Comparisons, 2007 December 2010 415 KB

Market Intelligence Report
Market Intelligence - Previous Reports
Market Intelligence Report Report Published Pdf
Combination Inhalers for Asthma, 2018 April 2020 4 MB
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs for Retinal Conditions, 2017 December 2018 1 MB
Biologic Response Modifier Agents, 2015 - Supplement: 2017 September 2018 875 KB
Biologic Response Modifier Agents, 2015 October 2016 2.71 MB

Back to top

Focused Reports

Chartbook

Expensive Drugs for Rare Diseases: Canadian Trends and International Comparisons, 2011–2020
Published: January 2022
PDF 1.2 MB

Previous Chartbooks

Report

Other NPDUIS Studies

Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20
Published: September 2022
PDF 710 KB

Previous Reports

Previous chartbooks and reports

Previous Chartbooks
Chartbook
Expensive Drugs for Rare Diseases Chartbook Published Pdf
Oncology Medicines in Canada: Trends and International Comparisons, 2010–2019 October 2020 1.5 MB
Biologics in Canada, 2018 May 2020 -
Part 1: Market Trends May 2020 1.35 MB
Part 2: Biosimiliar Savings May 2020 387 KB
The market for prescription oral solid opioids, 2010 to 2017 January 2019 893 KB

Previous Reports
Previous Report
EDrug Shortages in Canada Previous Reports Published Pdf
Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13 April 2014 3.07 MB
The Drivers of Prescription Drug Expenditures – A Methodological Report December 2013 1.54 MB
The Use of Blood Glucose Test Strips in Select Public Drug Plans, 2008 April 2013 666 KB
Wholesale Up-charge Policies of Canada's Public Drug Plans December 2011 - Revised January 2012 260 KB
The Impact of Generic Entry on the Utilization of the Ingredient September 2011 - Revised May 2012 800 KB
Public Drug Plan Dispensing Fees: A Cost-Driver Analysis, 2001/02 to 2007/08 September 2011 813 KB
Baby-Boomer Effect on Prescription Expenditures and Claims December 2010 545 KB
Use of the World Health Organization Defined Daily Dose in Canadian Drug Utilization and Cost Analyses December 2010 838 KB

Journal Articles

2024

2023

Posters & Presentations

Poster Presentations

2024
Posters & Presentations Pdf
Do higher prices provide protection against drug shortages? Real-world evidence lessons from Canada 154 KB
Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015–2021: a repeated cross-sectional study 442 KB
Competition in generic drug markets: international progress and room for improvement, 2010-2021 454 KB
Cost drivers for Canada’s public and private drug plans during the COVID-19 pandemic: a 2019-2022 comparative analysis 539 KB
Analyzing Drug Shortages and Pricing: Lessons from Canada 358 KB

Previous Posters

2023 2022 2021 2019 2018 2017 2016 2015 2014

2023
2023
Posters & Presentations Posters Pdf
The missing claimants of the pandemic: Who went without claims in Canada during the first two years of the COVID-19 pandemic and what does it mean for public and private drug plans? 579 KB
International Generic Availability Improvements Between 2010 and 2021 929 KB
Pipeline Trends Shaping the Future of Drug Development 418 KB
Biosimilars in Canada: Policies to Promote Switching and What It Means for Payers 254 KB
The Future of COVID-19: What's Next in the Drug Pipeline 669 KB

2022
2022
Posters & Presentations Posters Pdf
Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20 733 KB
The COVID-19 Pipeline: Vaccines and Treatments on the Horizon 945 KB
Alignment between the estimated therapeutic value of medicines and their Canadian prices 1 MB
The missing claimants of 2020: Who went without claims in Canada during the first year of the COVID-19 pandemic and what does it mean for public and private insurers? 1 MB
The COVID-19 Pipeline: Vaccines and Treatments on the Horizon 379 KB
Insight into approvals, marketing, and pricing of new medicines in Canadian and international markets 311 KB
The Cost of Drug Shortages for Canadian Insurers 318 KB
Canada’s Evolving Market for Biosimilars and What It Means for Payers 507 KB

2021
2021
Posters & Presentations Posters Pdf
Biosimilars in Canada: building momentum in the wake of recent switching policies 435 KB
Playing catch-up: where Canada stands three years into the pCPA–CGPA generics pricing initiative 383 KB
A pan-Canadian comparison of coverage for hospital and take-home oncology medicines 429 KB
Changes in Canadian Guidelines for Conducting Budget Impact Analysis 1.1 MB

2019
2019
Posters & Presentations Posters Pdf
Biosimilars in Canada: Current Environment and Future Opportunity 647 KB
Early insight into new medicine launches in Canadian and international markets 765 KB
Generic Drug Pricing in Canada: Closing the Gap 685 KB
Uncovering the forces driving costs in Canada’s public drug plans, 2017/18 560 KB
The Oncology Drug Market: A High-Growth, High-Price Therapeutic Area 546 KB
Combination asthma inhalers in Canada: locked on high prices 497 KB
Alignment of oncology drug coverage across Canada 1.30 MB
Pressures behind the rising costs in Canadian private drug plans, 2018 588 KB

2018
2018
Posters & Presentations Posters Pdf
The New Drug Landscape: International Availability and Pricing 375 KB
Generic Drugs in Canada, 2016 407 KB
Cost Drivers of Public Drug Plans in Canada, 2016/17 406 KB
Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2017 556 KB
The Cost of Drugs for Age-related Macular Degeneration in Canada and Internationally 821 KB
The Cost of New Oral Anti-diabetic Drugs in Canada and Internationally 2.29 MB
Cost Drivers of Private Drug Plans in Canada, 2017 755 KB

2017
2017
Posters & Presentations Posters Pdf
Potential Savings from Biosimilars in Canada 1.56 MB
The Canadian Market for Biologic Response Modifier Agents, 2015 305 KB
Generic Drugs in Canada, 2015 369 KB
A Review of Public Coverage of CDR Reviewed Drugs 354 KB
A Review of Public and Private Coverage of iJODR/pCODR Reviewed Drugs 325 KB
Potential Savings from Biosimilars in Canada 440 KB

2016
2016
Posters & Presentations Posters Pdf
Orphan Drug Launch Monitor (ODLM) 324 KB
Cost Pressures in the Canadian Hospital Drug Market, 2006–2014 373 KB
The Use of Diabetes Drugs in Canadian Public Drug Plans 369 KB
Private Drug Plans in Canada: Cost Drivers, 2008 to 2015 400 KB
New Drug Launch Monitor, 2009-2015 373 KB
Cost Pressure of the New Hepatitis C Drugs in Canada 310 KB
Private Drug Plans in Canada: High-Cost Drugs and Beneficiaries, 2005 to 2015 296 KB

2015
2015
Posters & Presentations Posters Pdf
Tamper-Resistant Properties of Drugs Regulations – Cost Impact Analysis, 2019 1.23 MB
Generic Drugs in Canada, 2013 373 KB
Cost Drivers of Private Drug Plans in Canada, 2012/13 400 KB
Cost Drivers of Public Drug Plans in Canada, 2012/13 1021 KB
The Use of Gabapentin in Public Drug Plans 1480 KB
Monitoring New Drugs in Canada: A Multifaceted Approach 326 KB
Generic Drugs in Canadian Private Plans, 2005–2013 338 KB

2014
2014
Posters & Presentations Posters Pdf
Private Drug Plans in Canada 695 KB
New Drug Pipeline Monitor 378 KB

Back to top

Supporting Information

These documents provide background material to supplement the NPDUIS analytical studies:

Canadian Public Drug Plan Designs and Policies

Back to top

Resources

Reference Documents

Methods

Foreign-to-Canadian Price RatiosPDF 176 KB

General Information

Budget Impact Analysis Guidelines

Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
Published: June 2020
PDF .87 MB

Back to top

Page details

Date modified: